Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Net Cash Flow (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Net Cash Flow for 11 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 546.6% year-over-year to $4.5 million, compared with a TTM value of -$207514.0 through Sep 2025, down 314.88%, and an annual FY2024 reading of $1.4 million, up 138.84% over the prior year.
  • Net Cash Flow was $4.5 million for Q3 2025 at Kiora Pharmaceuticals, up from -$2.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $28.9 million in Q1 2024 and bottomed at -$24.7 million in Q2 2024.
  • Average Net Cash Flow over 5 years is $205254.1, with a median of -$2.1 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1229.41% in 2024, while the deepest fall reached 643.27% in 2024.
  • Year by year, Net Cash Flow stood at -$3.2 million in 2021, then increased by 12.37% to -$2.8 million in 2022, then dropped by 8.55% to -$3.1 million in 2023, then skyrocketed by 42.31% to -$1.8 million in 2024, then soared by 352.45% to $4.5 million in 2025.
  • Business Quant data shows Net Cash Flow for KPRX at $4.5 million in Q3 2025, -$2.9 million in Q2 2025, and -$31417.0 in Q1 2025.